Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over (HST20)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 5 May 2022
Epilepsies in children, young people and adults (NG217)Product type:GuidanceProgramme:NICE guidelinePublished: 27 April 2022
Atidarsagene autotemcel for treating metachromatic leukodystrophy (HST18)Product type:GuidanceProgramme:Highly specialised technologies guidancePublished: 28 March 2022
Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education (NG213)Product type:GuidanceProgramme:NICE guidelinePublished: 9 March 2022
Palforzia for treating peanut allergy in children and young people (TA769)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 2 February 2022
Risdiplam for treating spinal muscular atrophy (TA755)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 16 December 2021
Liraglutide for managing obesity in people aged 12 to 17 years (terminated appraisal) (TA749)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 December 2021
Diabetes (type 1 and type 2) in children and young people: diagnosis and management – periodontal diseaseStatus:In developmentProgramme:NICE guidelineExpected publication date: 29 June 2022
Social, emotional and mental wellbeing in primary and secondary educationStatus:In developmentProgramme:NICE guidelineExpected publication date: 6 July 2022
Self harm: assessment, management and preventing recurrenceStatus:In developmentProgramme:NICE guidelineExpected publication date: 6 July 2022
Urinary tract infection in under 16s: diagnosis and managementStatus:In development | In consultationProgramme:NICE guidelineConsultation end date: 25 May 2022Expected publication date: 27 July 2022
Otitis media with effusion in under 12sStatus:In developmentProgramme:NICE guidelineExpected publication date: 28 September 2023
Maternal and child nutritionStatus:In developmentProgramme:NICE guidelineExpected publication date: 22 November 2023
Diabetes (type 1 and type 2) in children and young people: diagnosis and management - medicines for type 2 diabetes (update)Status:In developmentProgramme:NICE guidelineExpected publication date: 3 January 2024
Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Asfotase alfa for treating paediatric-onset hypophosphatasia (review of HST6) [ID3927]Status:Awaiting developmentProgramme:Highly specialised technologies guidanceExpected publication date: TBC
Beremagene geperpavec for treating dystrophic epidermolysis bullosa in children, young people and adults [ID3959]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Vertebral body tethering for idiopathic scoliosis in children and young peopleStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: TBC
Liposomal cytarabine–daunorubicin for treating relapsed or refractory acute myeloid leukaemia in people aged 1 to 21 years [ID4017]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TS ID 10085]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Ganaxolone for treating seizures caused by CDKL5 deficiency disorder in people 2 years and over [ID3988]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Baricitinib for treating moderate to severe atopic dermatitis in children and young people aged 2 to 17 [TS ID 10639]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Darunavir plus cobicistat fixed dose combination for paediatric human immunodeficiency virus 1 infection [TS ID 10722]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Somatrogon for treating growth disturbance in children and young people aged 3 and over [ID5086]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people 1 to 17 years [ID 5104]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Dupilumab for children with severe atopic dermatitis [TS ID 10434]Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Minimally invasive deformity correction system for the treatment of adolescent idiopathic scoliosisStatus:Awaiting developmentProgramme:Interventional procedures guidanceExpected publication date: TBC